02:31 , Dec 13, 2014 |  BC Extra  |  Clinical News

Alnylam outlines R&D strategy

At its R&D day on Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) refined its focus on developing RNAi therapeutics across three areas: hepatic infectious disease, genetic medicines and cardiometabolic disease. The company said it is targeting specific...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Alnylam infectious news

Alnylam unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the Study of Liver Diseases (AASLD) meeting. The company's ALN-HDV is designed to treat hepatitis delta...
02:16 , Nov 12, 2014 |  BC Extra  |  Company News

Alnylam adds to hepatic pipeline

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) unveiled two new RNAi therapeutic candidates in its hepatic infectious diseases portfolio at the American Association for the Study of Liver Diseases (AASLD) meeting. The company's ALN-HDV is designed to treat...